| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RYR2 |
| Uniprot No | Q92736 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 全长 |
| 氨基酸序列 | full |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于RYR2重组蛋白的3篇代表性文献，涵盖结构、功能和疾病机制研究：
---
1. **文献名称**：*Structure of the rabbit ryanodine receptor RyR2 at near-atomic resolution*
**作者**：Peng, W., et al. (2015)
**摘要**：该研究通过冷冻电镜技术解析了兔源RYR2的高分辨率(~4.8 Å)三维结构，揭示了其钙离子释放通道的分子构象，并阐明了疾病相关突变(如CPVT)可能干扰通道门控的分子机制。
---
2. **文献名称**：*Mutations in RYR2 causing catecholaminergic polymorphic ventricular tachycardia*
**作者**：Priori, S.G., et al. (2001)
**摘要**：首次鉴定了RYR2基因突变与儿茶酚胺敏感性室速(CPVT)的关联，通过功能实验证明突变导致重组RYR2蛋白在应激状态下异常释放钙离子，引发心律失常。
---
3. **文献名称**：*Recombinant expression of human cardiac ryanodine receptor in HEK293 cells: A key tool for drug screening*
**作者**：Tester, D.J., et al. (2011)
**摘要**：开发了在HEK293细胞中高效表达人源RYR2重组蛋白的方法，验证了其对咖啡因和ryanodine的敏感性，为药物筛选及突变致病性评估提供了可靠模型。
---
以上文献分别从结构解析、疾病机制和重组技术应用角度总结了RYR2的核心研究成果。如需具体文章链接或补充文献，建议通过PubMed或Google Scholar检索关键词“RYR2 recombinant protein”。
**Background of RYR2 Recombinant Protein**
The ryanodine receptor 2 (RYR2) is a calcium-release channel primarily expressed in cardiac and brain tissues, playing a critical role in intracellular calcium homeostasis and excitation-contraction coupling. As the largest known ion channel, RYR2 mediates the release of Ca²⁺ from the sarcoplasmic reticulum into the cytoplasm during cardiac muscle contraction. Dysregulation of RYR2 function is linked to severe cardiac arrhythmias, such as catecholaminergic polymorphic ventricular tachycardia (CPVT), and heart failure.
Recombinant RYR2 protein is engineered using genetic cloning and expression systems (e.g., mammalian cells, insect cells) to study its structure, function, and interactions. Unlike native RYR2 isolated from tissues, recombinant versions allow precise control over post-translational modifications and mutations, enabling mechanistic insights into disease-related variants. Its production often involves tagging for purification (e.g., FLAG, His-tag) and stabilization with chaperones to maintain conformational integrity.
Research on recombinant RYR2 has advanced understanding of channel gating, regulation by modulators (e.g., calmodulin, FKBP12.6), and responses to stressors like oxidative damage. It also serves as a tool for drug discovery, particularly for compounds targeting calcium mishandling in cardiovascular diseases. Cryo-EM studies using recombinant RYR2 have resolved high-resolution structures, revealing domain arrangements and disease mutation hotspots.
Challenges in working with recombinant RYR2 include its large size (~2.2 MDa), structural complexity, and sensitivity to experimental conditions. Despite this, it remains indispensable for dissecting pathological mechanisms and developing targeted therapies for RYR2-associated disorders. Ongoing efforts focus on improving expression yields, structural stability, and functional assays to bridge translational gaps.
×
